<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834171</url>
  </required_header>
  <id_info>
    <org_study_id>MA-RES-08-003</org_study_id>
    <nct_id>NCT00834171</nct_id>
  </id_info>
  <brief_title>A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <brief_summary>
    <textblock>
      Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes
      while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and
      tobramycin (0.3%)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Elevated Intraocular Pressure (IOP) During Treatment</measure>
    <time_frame>55 days</time_frame>
    <description>Mean elevated IOP during treatment. IOP is a measurement of the fluid pressure inside the eye. IOP was recorded any time an elevation of IOP (increase of 5 mmHg or more) occurred while using study treatment. The median duration of treatment at the time of observed IOP elevation was 55 days.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Loteprednol etabonate ophthalmic suspension 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Loteprednol etabonate (0.5%) and tobramycin (0.3%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate ophthalmic suspension 0.5%</intervention_name>
    <description>Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician</description>
    <arm_group_label>1</arm_group_label>
    <other_name>LOTEMAX速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate (0.5%) and tobramycin (0.3%).</intervention_name>
    <description>Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Zylet速</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Data to be collected will include: Patient Demographics (age, gender, race, eye color),
        medical and ophthalmic history, active ophthalmic disease, active systemic diseases,
        concomitant medications, procedure/condition for which Lotemax速/Zylet速 were prescribed,
        underlying etiology requiring PK (if applicable), history of prior ocular surgery, prior
        history of steroid response, history of glaucoma, start/stop date of steroid treatment, IOP
        before and after steroid treatment, treatment-related adverse events, and any other
        notes/information that the investigator feels may be important.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient who experienced an IOP spike while using Lotemax or Zylet will be included

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Maclean</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>August 17, 2011</results_first_submitted>
  <results_first_submitted_qc>August 17, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2011</results_first_posted>
  <last_update_submitted>August 17, 2011</last_update_submitted>
  <last_update_submitted_qc>August 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Vice President Medical Affairs</name_title>
    <organization>Allergan, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Loteprednol Etabonate Ophthalmic Suspension 0.5%</title>
          <description>Loteprednol etabonate ophthalmic suspension 0.5%</description>
        </group>
        <group group_id="P2">
          <title>Loteprednol Etabonate (0.5%) and Tobramycin (0.3%)</title>
          <description>Loteprednol etabonate (0.5%) and tobramycin (0.3%)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Loteprednol Etabonate Ophthalmic Suspension 0.5%</title>
          <description>Loteprednol etabonate ophthalmic suspension 0.5%</description>
        </group>
        <group group_id="B2">
          <title>Loteprednol Etabonate (0.5%) and Tobramycin (0.3%)</title>
          <description>Loteprednol etabonate (0.5%) and tobramycin (0.3%)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Baseline characteristics for age only analyzed for total study not for individual arms.</measurement>
                    <measurement group_id="B2" value="NA">Baseline characteristics for age only analyzed for total study not for individual arms.</measurement>
                    <measurement group_id="B3" value="58.8" lower_limit="17" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There were 33 females enrolled in the entire study. Baseline characteristics for gender only analyzed for total study not for individual arms.</measurement>
                    <measurement group_id="B2" value="NA">There were 33 females enrolled in the entire study. Baseline characteristics for gender only analyzed for total study not for individual arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There were 17 males enrolled in the entire study. Baseline characteristics for gender only analyzed for total study not for individual arms.</measurement>
                    <measurement group_id="B2" value="NA">There were 17 males enrolled in the entire study. Baseline characteristics for gender only analyzed for total study not for individual arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Elevated Intraocular Pressure (IOP) During Treatment</title>
        <description>Mean elevated IOP during treatment. IOP is a measurement of the fluid pressure inside the eye. IOP was recorded any time an elevation of IOP (increase of 5 mmHg or more) occurred while using study treatment. The median duration of treatment at the time of observed IOP elevation was 55 days.</description>
        <time_frame>55 days</time_frame>
        <population>Intent to treat, which included all patients in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate Ophthalmic Suspension 0.5%</title>
            <description>Loteprednol etabonate ophthalmic suspension 0.5%</description>
          </group>
          <group group_id="O2">
            <title>Loteprednol Etabonate (0.5%) and Tobramycin (0.3%)</title>
            <description>Loteprednol etabonate (0.5%) and tobramycin (0.3%)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Elevated Intraocular Pressure (IOP) During Treatment</title>
          <description>Mean elevated IOP during treatment. IOP is a measurement of the fluid pressure inside the eye. IOP was recorded any time an elevation of IOP (increase of 5 mmHg or more) occurred while using study treatment. The median duration of treatment at the time of observed IOP elevation was 55 days.</description>
          <population>Intent to treat, which included all patients in the study.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="6.9"/>
                    <measurement group_id="O2" value="23.9" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Loteprednol Etabonate Ophthalmic Suspension 0.5%</title>
          <description>Loteprednol etabonate ophthalmic suspension 0.5%</description>
        </group>
        <group group_id="E2">
          <title>Loteprednol Etabonate (0.5%) and Tobramycin (0.3%)</title>
          <description>Loteprednol etabonate (0.5%) and tobramycin (0.3%)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Glaucoma surgery</sub_title>
                <description>Type of Glaucoma Surgery:
Baerveldt tube shunt (2 patients)
Cytophotocoagulation diode laser (1 patient)
Selective laser trabeculoplasty (1 patient)</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Medical Affairs</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

